SCHEMBL19033109

SCHEMBL19033109

CC(C)(C)[Si](C)(C)O[C@@H]1C[C@H](n2cc(CO)c3c(Cl)ncnc32)O[C@@H]1CO

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADK P55263 9/20 0.40
▸ SLC29A1 Q99808 1/20 0.40
▸ HIF1A Q16665 2/20 0.35
▸ KDM4E B2RXH2 2/20 0.33
▸ PRMT5 O14744 1/20 0.33
▸ METTL3 Q86U44 1/20 0.33
▸ TP53 P04637 2/20 0.33
▸ HTT P42858 2/20 0.33
▸ PNP P00491 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ PDE4D Q08499 1/20 0.33
▸ PDE3A Q14432 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ RXFP1 Q9HBX9 1/20 0.33
▸ MAPK1 P28482 2/20 0.31
▸ CYP1A2 P05177 1/20 0.31
▸ STAT6 P42226 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ ALOX15 P16050 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16728050 0.94 ADK (0.35) ADKSLC29A1HIF1APRMT5METTL3
SCHEMBL14680069 0.94 ADK (0.35) ADKSLC29A1HIF1APRMT5METTL3
SCHEMBL19033104 0.94 ADK (0.39) ADKSLC29A1HIF1AKDM4EPRMT5
SCHEMBL19603979 0.92 ADK (0.36) ADKSLC29A1HIF1APRMT5METTL3
SCHEMBL10178599 0.92 ADK (0.36) ADKSLC29A1HIF1APRMT5METTL3
SCHEMBL19603990 0.89 ADK (0.53) ADKSLC29A1HIF1APRMT5METTL3
SCHEMBL15483516 0.85 ADK (0.34) ADKSLC29A1PRMT5METTL3
SCHEMBL14680026 0.85 ADK (0.34) ADKSLC29A1PRMT5METTL3
SCHEMBL19603991 0.85 ADK (0.37) ADKSLC29A1HIF1AKDM4EPRMT5
SCHEMBL10178238 0.83 ADK (0.35) ADKSLC29A1PRMT5METTL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307565-B1 REVERSIBLE NUCLEOSIDES AND NUCLEOTIDES TERMINATORS AND THEIR USE IN DNA SEQUENCING LASERGEN INC (US) 2017-11-29 — — EP disclosed
US-20170327886-A1 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING LASERGEN, INC. (US) 2017-11-16 — — US disclosed
US-9689035-B2 3′-OH unblocked, fast photocleavable terminating nucleotides and methods for nucleic acid sequencing LASERGEN, INC. (US) 2017-06-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170327886-A1 3'-OH UNBLOCKED, FAST PHOTOCLEAVABLE TERMINATING NUCLEOTIDES AND METHODS FOR NUCLEIC ACID SEQUENCING RNGTT, NT5C3B, NSUN2 ADK 688/4885SLC29A1 363/4885HIF1A 3333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback